ArticleSchizophrenia research2016
Evaluating the dopamine hypothesis of schizophrenia in a large-scale genome-wide association study.
Article in Schizophrenia research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Environmental factors contributing to negative symptoms in youth at clinical high risk for psychosis and outpatients with schizophrenia.Social psychiatry and psychiatric epidemiology · 2024Article
- New clues for the role of cerebellum in schizophrenia and the associated cognitive impairment.Frontiers in cellular neuroscience · 2024Review
- The Role of Dopaminergic Genes in Probabilistic Reinforcement Learning in Schizophrenia Spectrum Disorders.Brain sciences · 2021Article
- Reproducing the dopamine pathophysiology of schizophrenia and approaches to ameliorate it: a translational imaging study with ketamine.Molecular psychiatry · 2021Article
- Estrogens in schizophrenia: progress, current challenges and opportunities.Current opinion in psychiatry · 2021Review
- New information of dopaminergic agents based on quantum chemistry calculations.Scientific reports · 2020Article
- Fifty Years of Research on Schizophrenia: The Ascendance of the Glutamatergic Synapse.The American journal of psychiatry · 2020Review
- Effects of interactions between variation in dopaminergic genes, traumatic life events, and anomalous self-experiences on psychosis proneness: Results from a cross-sectional study in a nonclinical sample.European psychiatry : the journal of the Association of European Psychiatrists · 2020Article
- Neurobehavioral changes arising from early life dopamine signaling perturbations.Neurochemistry international · 2020Review
- Dopamine and glutamate in schizophrenia: biology, symptoms and treatment.World psychiatry : official journal of the World Psychiatric Association (WPA) · 2020Article
- Association between DRD2 and ANKK1 polymorphisms with the deficit syndrome in schizophrenia.Annals of general psychiatry · 2020Article
- Polymorphisms in Dopaminergic Genes in Schizophrenia and Their Implications in Motor Deficits and Antipsychotic Treatment.Frontiers in neuroscience · 2019Article
- New Targets for Schizophrenia Treatment beyond the Dopamine Hypothesis.International journal of molecular sciences · 2017Review
- The Role of Genes, Stress, and Dopamine in the Development of Schizophrenia.Biological psychiatry · 2017Review
- Epigenetic profiling of human brain differential DNA methylation networks in schizophrenia.BMC medical genomics · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundThe dopamine hypothesis, which posits that dysregulation of the dopaminergic system is etiologic for schizophrenia, is among the most enduring biological theories in psychiatry. Although variation within genes related to dopaminergic functioning has been associated with schizophrenia, an aggregate test of variation, using the largest publicly available schizophrenia dataset, has not previously been conducted.
methodsWe first identified a core set of 11 genes involved in the synthesis, metabolism, and neurotransmission of dopamine. We then extracted summary statistics of markers falling within, or flanking, these genes from the Psychiatric Genomics Consortium's most recent schizophrenia mega-analysis results. We conducted aggregate tests for enrichment of dopamine-related pathways for association with schizophrenia.
resultsWe did not detect significant enrichment of signals across the core set of dopamine-related genes. However, we did observe modest to strong enrichment of genetic signals within the DRD2 locus.
conclusionsWithin the limits of available power, common sequence variation within core genes of the dopaminergic system is not related to risk of schizophrenia. This does not preclude a role of dopamine, or dopamine-related genes, in the clinical presentation of schizophrenia or in treatment response. However, it does suggest that the genetic risk for schizophrenia is not substantially affected by common variation in those genes which, collectively, critically impact dopaminergic functioning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.